MRI, BioCampus Montpellier, UAR 3426 CNRS - US 09 INSERM - UM
contact: alexandre.djiane@inserm.fr
Dept of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Ms., USA
contact: alexandre.djiane@inserm.fr
Séminaire en distanciel, un lien Zoom sera diffusé la semaine précédente
Dept of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Ms., USA
contact: alexandre.djiane@inserm.fr
Séminaire en distanciel, un lien Zoom sera diffusé la semaine précédente
CRCL, INSERM U1052/CNRS UMR 5286, Centre Léon Bérard, Université Lyon 1
contact: nathalie.bonnefoy@inserm.fr
CRCL, INSERM U1052/CNRS UMR 5286, Centre Léon Bérard, Université Lyon 1
contact: nathalie.bonnefoy@inserm.fr
Immune Microenvironment and Immunotherapy Lab, UMR1135 Inserm, Hopital Pitié-Salpêtriere, Paris.
contact: nathalie.bonnefoy@inserm.fr
Immune Microenvironment and Immunotherapy Lab, UMR1135 Inserm, Hopital Pitié-Salpêtriere, Paris.
contact: nathalie.bonnefoy@inserm.fr
University of Gent, Experimental Cancer Research Lab, Belgium
Contact: jean-pierre.pouget@inserm.fr
Some more on the speaker:
Since his PhD, he has been working on cancer-associated fibroblasts (CAFs) in colon cancer progression (De Wever et al., FASEBJ 2004, J Pathol 2003, J Cell Science 2004 over 1000 cumulative WOS citations). I He expanded his research into adipose tissue during his post-doc (Lapeire et al., Cancer Res 2014) and the secretory mechanisms of pro-metastatic signals (Hendrix et al., JNCI 2010, Cancer Res 2010). His current lab woks on tumor-environment interactions including design of model systems (De Jaeghere et al., Biomaterials 2018), response to therapy of CAFs (Tommelein et al., Cancer Res 2018), and exploitation of CAFs as therapy (De Vlieghere et al., Biomaterials 2015) and extracellular vesicles with the Hendrix lab (De Wever and Hendrix EMBOJ 2019).
University of Gent, Experimental Cancer Research Lab, Belgium
Contact: jean-pierre.pouget@inserm.fr
Some more on the speaker:
Since his PhD, he has been working on cancer-associated fibroblasts (CAFs) in colon cancer progression (De Wever et al., FASEBJ 2004, J Pathol 2003, J Cell Science 2004 over 1000 cumulative WOS citations). I He expanded his research into adipose tissue during his post-doc (Lapeire et al., Cancer Res 2014) and the secretory mechanisms of pro-metastatic signals (Hendrix et al., JNCI 2010, Cancer Res 2010). His current lab woks on tumor-environment interactions including design of model systems (De Jaeghere et al., Biomaterials 2018), response to therapy of CAFs (Tommelein et al., Cancer Res 2018), and exploitation of CAFs as therapy (De Vlieghere et al., Biomaterials 2015) and extracellular vesicles with the Hendrix lab (De Wever and Hendrix EMBOJ 2019).
Institut de Génétique Humaine, CNRS/Université de Montpellier
contact: celine.gongora@inserm.fr
Institut de Génétique Humaine, CNRS/Université de Montpellier
contact: celine.gongora@inserm.fr
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
"Research in Dr Kruse's lab aims to elucidate the molecular basis of transmembrane signaling through the use of biochemistry, pharmacological studies, and structural biology. He is particularly interested in signaling pathways with connections to human health and disease, including G protein-coupled receptors and other transmembrane receptors. In the long term, he aims to leverage a detailed molecular understanding of these pathways to facilitate the development of new and better therapeutics."
Plus d'informations : https://kruse.hms.harvard.edu/home
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de